Tags

Type your tag names separated by a space and hit enter

Current pharmacological treatments for COVID-19: What's next?
Br J Pharmacol. 2020 11; 177(21):4813-4824.BJ

Abstract

Since December 2019 SARS-Cov-2 was found responsible for the disease COVID-19, which has spread worldwide. No specific therapies/vaccines are yet available for the treatment of COVID-19. Drug repositioning may offer a strategy and a number of drugs have been repurposed, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab. This paper describes the main pharmacological properties of such drugs administered to patients with COVID-19, focusing on their antiviral, immune-modulatory and/or anti-inflammatory actions. Where available, data from clinical trials involving patients with COVID-19 are reported. Preliminary clinical trials seem to support their benefit. However, such drugs in COVID-19 patients have peculiar safety profiles. Thus, adequate clinical trials are necessary for these compounds. Nevertheless, while waiting for effective preventive measures i.e. vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. Their results will help us in defining the best way to treat COVID-19 and reducing its symptoms and complications. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.

Authors+Show Affiliations

Department of Experimental Medicine, Università degli studi della Campania "Luigi Vanvitelli", Naples, Italy.Department of Experimental Medicine, Università degli studi della Campania "Luigi Vanvitelli", Naples, Italy.Department of Experimental Medicine, Università degli studi della Campania "Luigi Vanvitelli", Naples, Italy.Department of Experimental Medicine, Università degli studi della Campania "Luigi Vanvitelli", Naples, Italy.Department of Experimental Medicine, Università degli studi della Campania "Luigi Vanvitelli", Naples, Italy.Clinical Innovation Office, Università Campus Bio-medico, Rome, Italy.Department of Experimental Medicine, Università degli studi della Campania "Luigi Vanvitelli", Naples, Italy.Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.Department of Experimental Medicine, Università degli studi della Campania "Luigi Vanvitelli", Naples, Italy. Clinical Innovation Office, Università Campus Bio-medico, Rome, Italy.Department of Experimental Medicine, Università degli studi della Campania "Luigi Vanvitelli", Naples, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32329520

Citation

Scavone, Cristina, et al. "Current Pharmacological Treatments for COVID-19: What's Next?" British Journal of Pharmacology, vol. 177, no. 21, 2020, pp. 4813-4824.
Scavone C, Brusco S, Bertini M, et al. Current pharmacological treatments for COVID-19: What's next? Br J Pharmacol. 2020;177(21):4813-4824.
Scavone, C., Brusco, S., Bertini, M., Sportiello, L., Rafaniello, C., Zoccoli, A., Berrino, L., Racagni, G., Rossi, F., & Capuano, A. (2020). Current pharmacological treatments for COVID-19: What's next? British Journal of Pharmacology, 177(21), 4813-4824. https://doi.org/10.1111/bph.15072
Scavone C, et al. Current Pharmacological Treatments for COVID-19: What's Next. Br J Pharmacol. 2020;177(21):4813-4824. PubMed PMID: 32329520.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current pharmacological treatments for COVID-19: What's next? AU - Scavone,Cristina, AU - Brusco,Simona, AU - Bertini,Michele, AU - Sportiello,Liberata, AU - Rafaniello,Concetta, AU - Zoccoli,Alice, AU - Berrino,Liberato, AU - Racagni,Giorgio, AU - Rossi,Francesco, AU - Capuano,Annalisa, Y1 - 2020/05/15/ PY - 2020/04/08/received PY - 2020/04/16/revised PY - 2020/04/17/accepted PY - 2020/4/25/pubmed PY - 2020/10/28/medline PY - 2020/4/25/entrez KW - COVID-19 KW - antiinflammatory agents KW - antivirals KW - clinical practice KW - clinical research KW - immuno-modulatory agents KW - pharmacological treatments SP - 4813 EP - 4824 JF - British journal of pharmacology JO - Br J Pharmacol VL - 177 IS - 21 N2 - Since December 2019 SARS-Cov-2 was found responsible for the disease COVID-19, which has spread worldwide. No specific therapies/vaccines are yet available for the treatment of COVID-19. Drug repositioning may offer a strategy and a number of drugs have been repurposed, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab. This paper describes the main pharmacological properties of such drugs administered to patients with COVID-19, focusing on their antiviral, immune-modulatory and/or anti-inflammatory actions. Where available, data from clinical trials involving patients with COVID-19 are reported. Preliminary clinical trials seem to support their benefit. However, such drugs in COVID-19 patients have peculiar safety profiles. Thus, adequate clinical trials are necessary for these compounds. Nevertheless, while waiting for effective preventive measures i.e. vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. Their results will help us in defining the best way to treat COVID-19 and reducing its symptoms and complications. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc. SN - 1476-5381 UR - https://www.unboundmedicine.com/medline/citation/32329520/full_citation L2 - https://doi.org/10.1111/bph.15072 DB - PRIME DP - Unbound Medicine ER -